SG10201804330YA - Engineered high-affinity human t cell receptors - Google Patents
Engineered high-affinity human t cell receptorsInfo
- Publication number
- SG10201804330YA SG10201804330YA SG10201804330YA SG10201804330YA SG10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA
- Authority
- SG
- Singapore
- Prior art keywords
- tcrs
- cell receptors
- affinity
- affinity human
- engineered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907887P | 2013-11-22 | 2013-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201804330YA true SG10201804330YA (en) | 2018-07-30 |
Family
ID=53180203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804330YA SG10201804330YA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
| SG10201804335QA SG10201804335QA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804335QA SG10201804335QA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10023625B2 (ja) |
| EP (2) | EP3071593B1 (ja) |
| JP (4) | JP6697386B2 (ja) |
| KR (2) | KR102415259B1 (ja) |
| CN (2) | CN105873945B (ja) |
| AU (4) | AU2014352826B2 (ja) |
| BR (1) | BR112016011567A2 (ja) |
| CA (2) | CA2930852C (ja) |
| DK (1) | DK3071593T3 (ja) |
| ES (1) | ES2729406T3 (ja) |
| IL (2) | IL245468B (ja) |
| MX (3) | MX371202B (ja) |
| PL (1) | PL3071593T3 (ja) |
| PT (1) | PT3071593T (ja) |
| RU (2) | RU2740648C2 (ja) |
| SA (1) | SA516371174B1 (ja) |
| SG (2) | SG10201804330YA (ja) |
| TR (1) | TR201908404T4 (ja) |
| WO (2) | WO2015077615A1 (ja) |
| ZA (2) | ZA201603116B (ja) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1951281B1 (en) | 2005-10-17 | 2015-04-15 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| US20150104413A1 (en) | 2012-01-13 | 2015-04-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| HUE052541T2 (hu) | 2013-01-15 | 2021-05-28 | Memorial Sloan Kettering Cancer Center | Immunogén WT-1 peptidek és eljárások azok alkalmazására |
| CN105873945B (zh) | 2013-11-22 | 2020-07-17 | 伊利诺伊州大学理事会 | 工程化的高亲和力人类t细胞受体 |
| WO2017050884A1 (en) * | 2015-09-22 | 2017-03-30 | Julius-Maximilians-Universität Würzburg | A method for high level and stable gene transfer in lymphocytes |
| WO2017055635A1 (en) * | 2015-10-01 | 2017-04-06 | Ospedale San Raffaele S.R.L. | Tcr and uses thereof |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017112944A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| US11534461B2 (en) | 2016-11-14 | 2022-12-27 | Fred Hutchinson Cancer Center | High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof |
| AU2018234830B2 (en) * | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
| WO2018197492A1 (en) * | 2017-04-24 | 2018-11-01 | Ospedale San Raffaele S.R.L. | Tcr and peptides |
| JP7181517B2 (ja) * | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| CN112739339A (zh) * | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| CN114555790A (zh) * | 2019-08-20 | 2022-05-27 | 弗雷德哈钦森癌症研究中心 | Wt-1特异性t细胞免疫疗法 |
| WO2021163366A1 (en) * | 2020-02-12 | 2021-08-19 | Abbvie Inc. | Bispecific binding molecules |
| CN115461062A (zh) | 2020-04-28 | 2022-12-09 | 阿基里斯治疗英国有限公司 | T细胞疗法 |
| EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| CA3223074A1 (en) | 2021-06-22 | 2022-12-29 | Achilles Therapeutics Uk Limited | A method for producing antigen specific t cells |
| CN117957012A (zh) * | 2021-07-19 | 2024-04-30 | 得克萨斯州大学系统董事会 | 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4640561A (en) | 1985-11-15 | 1987-02-03 | Ford Motor Company | Flexible printed circuit connector |
| US5059413A (en) | 1988-04-18 | 1991-10-22 | Xoma Corporation | Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators |
| US5102990A (en) | 1989-08-09 | 1992-04-07 | Rhomed Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5299253A (en) | 1992-04-10 | 1994-03-29 | Akzo N.V. | Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| NZ507887A (en) | 1998-05-19 | 2002-12-20 | Avidex Ltd | Soluble T cell receptor |
| ATE370967T1 (de) | 1998-10-21 | 2007-09-15 | Altor Bioscience Corp | Polyspezifische bindemoleküle und deren verwendung |
| ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| CA2566363C (en) | 2004-05-19 | 2014-12-16 | Avidex Ltd | High affinity ny-eso t cell receptor |
| EP1756278B1 (en) | 2004-05-19 | 2008-09-17 | MediGene Ltd. | Method of improving t cell receptors |
| GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) * | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| WO2010075417A1 (en) * | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
| CA2751762A1 (en) | 2009-02-09 | 2010-08-12 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US10464987B2 (en) * | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| AU2010358291A1 (en) | 2010-07-28 | 2013-02-28 | Immunocore Ltd | T cell receptors |
| CA2812153C (en) | 2010-09-20 | 2020-06-30 | Biontech Ag | Antigen-specific t cell receptors and t cell epitopes |
| CN104395462B (zh) | 2012-05-03 | 2017-09-26 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| WO2014191465A1 (en) * | 2013-05-28 | 2014-12-04 | Møller Niels Iversen | Peptides derived from lawsonia intracellularis and their use in vaccination |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| CN105873945B (zh) | 2013-11-22 | 2020-07-17 | 伊利诺伊州大学理事会 | 工程化的高亲和力人类t细胞受体 |
| WO2016022400A1 (en) | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
-
2014
- 2014-11-21 CN CN201480071620.2A patent/CN105873945B/zh active Active
- 2014-11-21 WO PCT/US2014/066903 patent/WO2015077615A1/en active Application Filing
- 2014-11-21 AU AU2014352826A patent/AU2014352826B2/en active Active
- 2014-11-21 MX MX2016006620A patent/MX371202B/es active IP Right Grant
- 2014-11-21 MX MX2016006625A patent/MX2016006625A/es unknown
- 2014-11-21 PL PL14863490T patent/PL3071593T3/pl unknown
- 2014-11-21 EP EP14863490.0A patent/EP3071593B1/en active Active
- 2014-11-21 US US15/037,476 patent/US10023625B2/en active Active
- 2014-11-21 ES ES14863490T patent/ES2729406T3/es active Active
- 2014-11-21 SG SG10201804330YA patent/SG10201804330YA/en unknown
- 2014-11-21 PT PT14863490T patent/PT3071593T/pt unknown
- 2014-11-21 WO PCT/US2014/066892 patent/WO2015077607A1/en active Application Filing
- 2014-11-21 JP JP2016533163A patent/JP6697386B2/ja not_active Expired - Fee Related
- 2014-11-21 US US15/037,485 patent/US10344075B2/en active Active
- 2014-11-21 CA CA2930852A patent/CA2930852C/en active Active
- 2014-11-21 CA CA2930847A patent/CA2930847A1/en not_active Abandoned
- 2014-11-21 RU RU2016124179A patent/RU2740648C2/ru active
- 2014-11-21 DK DK14863490.0T patent/DK3071593T3/da active
- 2014-11-21 KR KR1020167016131A patent/KR102415259B1/ko active IP Right Grant
- 2014-11-21 BR BR112016011567A patent/BR112016011567A2/pt not_active Application Discontinuation
- 2014-11-21 SG SG10201804335QA patent/SG10201804335QA/en unknown
- 2014-11-21 TR TR2019/08404T patent/TR201908404T4/tr unknown
- 2014-11-21 JP JP2016533150A patent/JP6476182B2/ja active Active
- 2014-11-21 RU RU2016124163A patent/RU2729383C2/ru active
- 2014-11-21 KR KR1020167016132A patent/KR20160085345A/ko not_active Application Discontinuation
- 2014-11-21 AU AU2014352834A patent/AU2014352834B2/en not_active Ceased
- 2014-11-21 EP EP14864079.0A patent/EP3071594A4/en active Pending
- 2014-11-21 CN CN201480071635.9A patent/CN105899530B/zh not_active Expired - Fee Related
-
2016
- 2016-05-04 IL IL245468A patent/IL245468B/en active IP Right Grant
- 2016-05-04 IL IL245467A patent/IL245467B/en not_active IP Right Cessation
- 2016-05-10 ZA ZA2016/03116A patent/ZA201603116B/en unknown
- 2016-05-11 ZA ZA2016/03169A patent/ZA201603169B/en unknown
- 2016-05-20 MX MX2021006932A patent/MX2021006932A/es unknown
- 2016-05-21 SA SA516371174A patent/SA516371174B1/ar unknown
-
2018
- 2018-05-25 US US15/990,524 patent/US20190055298A1/en not_active Abandoned
-
2019
- 2019-10-17 JP JP2019190139A patent/JP6970724B2/ja active Active
- 2019-11-28 AU AU2019272003A patent/AU2019272003B2/en not_active Ceased
-
2021
- 2021-04-15 AU AU2021202274A patent/AU2021202274A1/en not_active Abandoned
- 2021-11-01 JP JP2021178468A patent/JP2022023196A/ja active Pending
-
2022
- 2022-01-27 US US17/586,652 patent/US20220396606A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201804330YA (en) | Engineered high-affinity human t cell receptors | |
| CY1123142T1 (el) | Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων | |
| PH12019502529A1 (en) | Materials and methods for engineering cells and uses thereof in immuno-oncology | |
| MX2017000646A (es) | Celulas geneticamente modificadas para terapia celular adoptiva. | |
| AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
| MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
| MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
| MX2019013498A (es) | Receptor de antigeno quimerico y metodos para usarlo. | |
| PH12016500395A1 (en) | Cell penetrating conjugates and methods of use thereof | |
| MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
| MX2023005612A (es) | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. | |
| EP4279579A3 (en) | Methods and compositions for natural killer cells | |
| IN2014DN09787A (ja) | ||
| MX364229B (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MX2014014337A (es) | Metodo de produccion de alta concentracion de celulas madre. | |
| WO2012021632A3 (en) | Generation and use of pluripotent stem cells | |
| AU2016335217A8 (en) | Antigen receptors and uses thereof | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| IN2015KN00329A (ja) | ||
| CY1123467T1 (el) | Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1 | |
| EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same | |
| PH12017500018A1 (en) | Myo-inositol and probiotics, and their use | |
| MX2021001981A (es) | Metodos para preparar un poloxamero para usar en medio de cultivo celular. | |
| MX365656B (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
| WO2016049510A3 (en) | Cell-based targeted delivery of pseudonomas exotoxin |